the First vaccine against lung cancer – One of the most deadly diseases with nearly 1.8 million deaths worldwide each year – is already a reality and is being applied in seven countries, including Spain. This medical breakthrough could help save the lives of hundreds of thousands of people thanks to its “innovative” potential, according to the scientific community. Clinical trials have been carried out on 130 patients who will receive the vaccine dose and immunotherapy. However, it should be noted that The vaccine is therapeutic, not preventive.That is, it is used to treat patients with cancer. BNT116, the first broad-spectrum vaccine for lung cancer Based on messenger RNA It has begun testing on humans.
How does the vaccine work?
The BNT116 vaccine uses the same methodology used to treat COVID-19. Messenger RNA. It seeks out an immune response through RNA, which means it tells the body to find and destroy cancer cells so they don’t come back. Although the vaccine destroys cancer cells, it’s different from chemotherapy in that it kills cells that are growing too fast. There are healthy cells that are also growing and can be killed. Instead, the vaccine aims to leave healthy cells intact and not harm the immune system. To be able to give this vaccine to those affected They must have completed all other cancer treatments. Lung and can not have other diseases.
The United States, Germany, Spain, the United Kingdom, Poland, Hungary and Turkey are the seven countries that have chosen this vaccine against lung cancer. Barcelona, Madrid, Santiago de Compostela, Seville and Valencia have eight centres that are part of this immunotherapy trial. The drug is manufactured by BioNTech. It is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.
First vaccine for the Regni unit
The first person to receive the vaccine in the UK is Janus, 67. He was diagnosed in May and soon after began chemotherapy and radiotherapy. These treatments didn’t work and now their hope is this vaccine. In an interview with Sky News “I feel good, it hasn’t hurt me yet. I don’t care if I’m first or 100th, “I think it would help me and others if the vaccine was produced more quickly.”
The patient receives six injections in half an hour on average: Each contains a different sequence of messenger RNA, the purpose of which is to reach cells and produce an antigen, which the immune system will recognize and activate its defense mechanisms, attacking the tumor. The patients who will participate in the trial were diagnosed with non-small cell lung cancer, the most common type of this tumor. Up to 85% of cancers detected are these. Patients will receive the vaccines once a week for a month and a half. After that, they will do so every three weeks for a year.
“Infuriatingly humble social media buff. Twitter advocate. Writer. Internet nerd.”
